Medication info
Empagliflozin/Metformin Hydrochloride Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Empagliflozin/Metformin Hydrochloride Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, oval, biconvex, film-coated tablet
Packaging
10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202201540 · Approved 2022.04.13 · Insurance code 647805800

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose is 1 tablet twice daily. The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients taking this medicine who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; if this occurs, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given with this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Contraindications, item 2)). Older adults In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with poor blood sugar control
  • cardiovascular disease
View approved original text

This medication is used as a treatment that helps control blood sugar in adults with type 2 diabetes by combining empagliflozin and metformin. It is intended for patients undergoing dietary therapy and exercise therapy. It is particularly effective for patients whose blood sugar is not adequately controlled, and it is important to consult with a healthcare professional regarding the treatment plan if cardiovascular disease is present. This medication helps improve blood sugar levels and aids in diabetes management.

How to take

Adult dose

The recommended dose is 1 tablet twice daily. The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients taking this medicine who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; if this occurs, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given with this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Contraindications, item 2)). Older adults In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is designed to help lower blood sugar levels. However, it should not be administered to patients with poor kidney function or those with acute infections, heart failure, or liver dysfunction. It is also advised that pregnant or breastfeeding women avoid this medication. This drug can rarely cause severe lactic acidosis, so if symptoms such as vomiting, abdominal pain, or difficulty breathing occur, medical advice should be sought immediately. Additionally, care is needed when using this drug with other diabetes medications due to the risk of hypoglycemia. Urinary or genital infections may occur, so patients should inform their healthcare provider if any symptoms arise. This medication may cause a decrease in fluid volume, so it should be used cautiously in patients who are dehydrated or elderly. If surgery is planned, discontinue this medication 48 hours before surgery and resume it only after kidney function has returned to normal. Regular blood tests to monitor kidney function and vitamin B12 levels are recommended. Avoiding alcohol is advisable as it may increase the risks of side effects from this medication. During treatment, if sudden weight loss, severe fatigue, or dizziness occurs, consult a healthcare provider immediately. Safety in children has not been established; hence, it is not used in this population. This medication must be taken exactly as prescribed, and patients should not discontinue or increase the dosage arbitrarily.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • constipation
Show 167 more
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema multiforme
  • urinary retention
  • interstitial nephritis
  • thirst
  • elevated serum lipids
  • increased blood creatinine
  • reduced glomerular filtration rate
  • vulvovaginitis
  • vulvar vaginitis
  • balanitis
  • perineal necrosis
  • decreased fluid volume
  • lactic acidosis
  • ketoacidosis
  • decreased and deficient vitamin B12
  • headache
  • dizziness
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • nasopharyngitis
  • upper respiratory infection
  • periodontitis
  • dental abscess
  • positional vertigo
  • sensory impairment
  • perceptual disturbances
  • amnesia
  • carotid artery stenosis
  • diabetic neuropathy
  • facial paralysis
  • intracranial aneurysm
  • memory disturbances
  • neuralgia
  • Parkinson's disease
  • polyneuropathy
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weakness
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral stones
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary stasis
  • urinary pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal hemorrhage
  • asthma
  • COPD
  • wet cough
  • allergic rhinitis
  • sputum retention
  • cough
  • anxiety
  • depression
  • sleep disorder
  • ear pain
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • vulvar pruritus
  • genital pruritus
  • unstable angina
  • hypertension
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to maintain the storage temperature between 1 to 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Orange-yellow, oval, biconvex, film-coated tablet

Package unit

10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.